Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Solís García del Pozo, Julián ^a   Solera, Javier ^b  

^a Department of Internal Medicine   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; MINOCYCLINE; NETILMICIN; OFLOXACIN; OXYTETRACYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ANTIBIOTIC THERAPY; ARTICLE; BRUCELLOSIS; CHILD; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOARTHROPATHY; OUTCOME ASSESSMENT; RELAPSE; SCHOOL CHILD; SPONDYLITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; FEMALE; MALE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BRUCELLOSIS; COST-BENEFIT ANALYSIS; DOXYCYCLINE; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; ODDS RATIO; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 84857674443     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032090     Document Type: Article

References (72)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV, (2006) The new global map of human brucellosis. Lancet Infect Dis 6: 91-99.
2. Afifi S, Earhart K, Azab MA, Youssef FG, El Sakka H, et al. (2005) Hospital-based surveillance for acute febrile illness in Egypt: A focus on community-acquired bloodstream infections. Am j Trop Med Hyg 73: 392-399.
3. Colmenero JD, Reguera JM, Martos F, Sanchez de Mora D, Delgado M, et al. (1996) Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 75: 195-211.
4. Joint WHO/FAO expert committee on brucellosis. 6th report (1986) WHO Tech Rep Ser 740: 1-132.
5. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, et al. (2007) Perspectives for the treatment of brucellosis in the 21st century: The Ioannina recommendations. PLOS medicine 4: 1872-1878.
6. Pappas G, Solera J, Akritidis N, Tsianos E, (2005) New approaches to the antibiotic treatment of brucelosis. Int J Antimicrobial Agents 26: 101-105.
7. Hall WH, (1990) Modern chemotherapy for brucellosis in humans. Rev Infect Dis 12: 1060-1099.
8. Ariza J, Gudiol F, Pallarés R, Rufí G, Fernandez-Viladrich P, (1985) Comparative trial of rifampin-doxycicline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother 28: 548-551.
9. Ariza J, Gudiol F, Pallarés R, Rufí G, Fernandez-Viladrich P, (1985) Comparative trial of cotrimoxazol versus tetracicline-streptomycin in treating human brucellosis. J Infect Dis 152: 1358-1359.
10. Acocella G, Bertrand A, Beytour J, Durrande JB, García Rodriguez JA, et al. (1989) Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrobial Chemoteraphy 23: 433-439.
11. Colmenero Castillo JD, Hernandez Marquez S, Reguera Iglesias JM, Cabrera Franquelo F, Rius Diaz F, et al. (1989) Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. Chemotherapy 35: 146-152.
12. Solera J, Martinez Alfaro E, Saez L, (1994) Metaanálisis sobre la eficacia de la combinación de rifampicina y doxiciclina en el tratamiento de la brucelosis humana. Med Clin (Barc) 102: 731-738.
13. Falagas ME, Bliziotis IA, (2006) Quinolones for treatmentof human brucellosis: critical review of the evidencefrom microbiological and clinical studies. Antimicrob Agents Chemother 50: 22-33.
14. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, et al. (2008) Treatment of human brucellosis: systematic review and meta-analysis of randomized controlled trials. BMJ 336 (7646): 701-704.
15. Bayindir Y, Sonmez E, Aladag A, Buyukberber N, (2003) Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: a prospective, randomized study. J Chemother 15: 466-471.
16. Ranjbar M, Keramat F, Mamani M, Rostami Kia A, Khalilian F, et al. (2007) Comparison between doxycycline-rifampin-amikacin and doxyxycline-rifampin regimens in the treatment of brucelosis. Int J Infect Dis 11: 152-156.
17. Solera J, Medrano F, Rodríguez M, Geijo P, Paulino J, (1991) Ensayo terapéutico comparativo y multicéntrico de rifampicina y doxiciclina frente a estreptomicina y doxiciclina en la brucelosis humana. Med Clin (Barc) 96: 649-653.
18. Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, et al. (1992) Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 117: 25-30.
19. Akova M, Uzun Ö, Erdal Akalin H, Hayran M, Ünal S, et al. (1993) Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemoter 37: 1831-1834.
20. Solera J, Rodriguez-Zapata M, Geijo P, Largo J, Paulino J, et al. (1995) Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemoter 39: 2061-2067.
21. Agalar C, Usubutun S, Turkyilmaz R, (1999) Ciprofloxacin and rifampin versus doxycycline and rifampin in the treatment of brucelosis. Eur J Clin Microbiol Infect Dis 18: 535-538.
22. Karabay O, Sencan I, Kayas D, Sahin I, (2004) Ofloxacin plus rifampin versus doxycycline plus rifampin in the treatment of brucellosis: a randomized clinical trial. BMC Infectious Diseases 4: 18 Available:http://www.biomedcentral.com/1471-2334-4-18.
23. Rodriguez Zapata M, Gamo Herranz A, de la Morena Fernández J, (1987) Comparative study of two regimens in the treatment of brucelosis. Chemioterapia 6 (Suppl 2): 360-362.
24. Cisneros JM, Viciana P, Colmenero J, Pachón J, Martinez C, et al. (1990) Multicenter prospective study of treatment of Brucella melitensis brucelosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother 34: 881-883.
25. Montejo JM, Alberola I, Gonzalez Zarate P, Alvarez A, Alonso J, et al. (1993) Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucelosis. Clin Infect Dis 16: 671-676.
26. Ersoy Y, Sonmez E, Tevfik MR, But AD, (2005) Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct 35: 210-212.
27. Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Akbar Valayati A, (2006) Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis 42: 1075-1080.
28. Hasanjani Roushan MR, Soleimani Amiri MJ, Janmohammadi N, Sadeghi Hadad M, Javanian M, et al. (2010) Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. J Antimicrob Chemother 65: 1028-1035.
29. Colmenero JD, Fernandez-Gallardo LC, Agúndez JAG, Sedeño J, Benítez J, et al. (1994) Possible implications of doxycycline-rifampin interaction for treatment of brucelosis. Antimicrob Agents Chemother 38: 2798-2802.
30. Lubani MM, Dudin KI, Sharda DC, Mana Ndhar DS, Araj GF, et al. (1989) A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 8: 75-78.
31. Solera J, Espinosa A, Martínez-Alfaro E, Sánchez L, Geijo P, et al. (1997) Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob Agents Chemother 41 (1): 80-84.
32. Solera J, Geijo P, Largo J, Rodríguez-Zapata M, Gijón J, et al. (2004) A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucelosis. Clin Infect Dis 39: 1776-1782.
33. Solera J, Espinosa A, Geijo P, Martinez-Alfaro E, Sáez L, et al. (1996) Treatment of human brucelosis with netilmicin and doxycicline. Clin Infect Dis 22: 441-445.
34. Solera J, Beato JL, Martinez-Alfaro E, Segura JC, de Tomás E, y el Grupo de Estudio de Castilla la Mancha de Enfermedades Infecciosas (2001) Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis 32 (3): 506-509.
35. El Miedani YM, El Gaafary M, Baddour M, Ahmed I, (2003) Human brucellosis: do we need to revise our therapeutic policy? J Rheumatol 30: 2666-2672.
36. Kalo T, Novi S, Nushi A, Dedja S, (1996) Ciprofloxacin plus doxycycline versus rifampicin plus doxycycline in the treatment of acute brucelosis. Méd Mal Infect 26: 587-589.
37. Saltoglu N, Tasova Y, Inal AS, Seki T, Aksu HS, (2002) Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J 23 (8): 921-924.
38. Keramat F, Ranjbar M, Mamani M, Hashemi SH, Zeraati F, (2009) A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline an doxycycline-rifampin in the treatment of brucellosis. Trop Doct 39: 207-210.
39. Alavi SM, Rajabzadeh AR, (2007) Comparison of two chemotherapy regimen: doxycycline-rifampicin and doxycycline cotrimoxazol in the brucellosis patients. Ahvaz, Iran, 2004-2006. Pak J Med Sci 23: 889-892.
40. Cascio A, Scarlata F, Giordano S, Antinori S, Colomba C, et al. (2003) Treatment of human brucellosis with rifampin plus minocycline. J Chemother 15: 248-252.
41. Lang R, Raz R, Sacks T, Shapiro M, (1990) Failure of prolongued treatment with ciprofloxacin in acute infections due to Brucella melitensis. J Antimicrob Chemother 26: 841-846.
42. Hasanjani Roushan MR, Esmailnejad Gangi SM, Asgarzadeh Ahmadi SA, (2004) Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs co-trimoxazole plus rifampin in brucellosis. Swiss med Wkly 134: 564-568.
43. Hasanjani Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M, (2006) Efficacy of cotrimoxazole and rifampin for 6-8 weeks of therapy in childhood brucellosis. Pediatr Infect Dis J 25: 544-545.
44. Alp E, Koc RK, Durak AC, Yildiz O, Aygen B, et al. (2006) Doxycycline plus streptomycin versus ciprofloxacin plus rifampin in spinal brucellosis. BMC Infect Dis 72 Available:http://www.biomedcentral.com/1471-2334-6-72.
45. Lang R, Dagan R, Potasman I, Einhorn M, Raz R, (1992) Failure of ceftriaxone in the treatment of acute brucellosis. Clin Infect Dis 14: 506-509.
46. Feiz JM, Sabbaghian H, Sohrabi F, (1973) A comparative study of therapeutic agents used for treatment of acute brucellosis. Br J Clin Pract 27: 410-413.
47. Grasso E, Conversa P, Mondino P, Spirolazzi MP, Dalmasso G, Raineri G, (1987) Su 295 casi di brucellosi trattati con moniciclina. Min Med 78: 1443-1447.
48. Khuri-Bulos N, Shaker K, (1991) Relapse of brucelosis following ofloxacin therapy. J Infect 22: 302-303.
49. Doganay M, Aygen B, (1992) Use of ciprofloxacin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 11: 74-75.
50. Al-Sibai MB, Halim MA, el-Shaker MM, Khan BA, Qadri SM, (1992) Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother 36: 150-152.
51. Shehabi A, Shakir K, el-Khateeb M, Qubain H, Fararjeh N, et al. (1990) Diagnosis and treatment of 106 cases of human brucellosis. J Infect 20: 5-10.
52. al-Idrissi HY, Uwaydah AK, Danso KT, Qutub H, al-Mousa MS, (1989) Ceftriaxone in the treatment of acute and subacute human brucellosis. J Int Med Res 17: 363-368.
53. Abramson O, Abu-Rashid M, Gorodischer R, Yagupsky P, (1997) Failure of short antimicrobial treatments for human brucellosis. Antimicrob Agents Chemother 41: 1621-1622.
54. Malik GM, (1998) Early clinical response to different therapeutic regimens for human brucellosis. Am J Trop Med Hyg 58: 190-191.
55. Aygen B, Doganay M, Sümerkan B, Yildiz O, Kayabas Ü, (2002) Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Méd Mal Infect 32: 485-493.
56. Barroso García P, Rodríguez-Contreras Pelayo R, Gil Extremera B, Maldonado Martín A, Guijarro Huertas G, et al. (2002) Estudio de 1595 casos de brucelosis en la provincia de Almería (1972-1998) según datos epidemiológicos de declaración de la enfermedad. Rev Clin Esp 202: 577-582.
57. Bosilkovski M, Krteva L, Dimzova M, Kondova I, (2007) Brucellosis in 418 patients from the Balkan peninsula: exposure-related differences in clinical manifestations, laboratory test results, and therapy outcome. Int J Infect Dis 11: 342-347.
58. Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Yousuf Khan M, (2000) Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect 40: 59-63.
59. Andriopoulos P, Tsironi M, Deftereos S, Aessopos A, Assimakopoulos G, (2007) Acute brucelosis: presentation, diagnosis, and treatment of 144 cases. Int J Infect Dis 11: 52-57.
60. AlShaalan M, Memish ZA, Al Mahmoud S, Alomari A, Khan MY, et al. (2002) Brucellosis in children: clinical observations in 115 cases. Int J Infect Dis 6: 182-186.
61. Savas L, Onlen Y, Savas N, Yapar AF, Aydin M, et al. (2007) Prospective evaluation of 140 patients with brucellosis in the southern region of Turkey. Infect Dis Clin Pract 15: 83-88.
62. Demirtürk N, Demirdal T, Erben N, Demir S, Asci Z, et al. (2008) Brucellosis: a retrospective evaluation of 99 cases and review of brucellosis treatment. Trop Doct 38: 59-62.
63. Franco MP, Mulder M, Gilman RH, Smits HL, (2007) Human brucellosis. Lancet Infect Dis 7: 775-786.
64. Pappas G, Siozopoulou V, Akritidis N, Falagas ME, (2007) Doxycycline-rifampin: physicians' inferior choice in brucelosis or how convenience reigns over science. J Infect 54: 459-462.
65. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, et al. (2010) Clinical manifestations and complications in 1028 cases of brucelosis: a retrospective evaluation and review of the literature. Int J infect Dis 14: e469-e478.
66. Ariza J, (2002) Brucelosis en el siglo XXI. Med Clin (Barc) 119: 339-344.
67. Straight TM, Martin GJ, (2002) Brucellosis. Curr Treatment Options Infect Dis 4: 447-456.
68. Pappas G, Papadimitriou P, Christou L, Akritidis N, (2006) Future trends in human brucellosis treatment. Expert Opin Investig Drugs 15: 1141-1149.
69. Pappas G, Memish ZA, (2007) Brucellosis in the middle East: a persistent medical, socioeconomic and political issue. J Chemother 19: 243-248.
70. Ariza J, Corredoira J, Pallarés R, Viladrich PF, Rufi G, et al. (1995) Characteristics of and risk factors for relapse of brucelosis in humans. Clin Infect Dis 20: 1241-1249.
71. Solera J, Martinez Alfaro E, Espinosa A, Castillejos ML, Geijo P, et al. (1998) Multivariate model for predicting relapse in human brucellosis. J infect 36: 85-92.
72. Villa LF (coord), (2010) Medimecum. Guía de terapia farmacológica. Ed. Wolters Kluwer Health Pharma Solutions España.